BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37970340)

  • 1. Small-molecule exhibits anti-tumor activity by targeting the RNA m
    Shu C; Gu MH; Zeng C; Shao WG; Li HY; Ma XH; Li MX; Cao YY; Zhang MJ; Zhao W; Zhao SL
    Am J Cancer Res; 2023; 13(10):4888-4902. PubMed ID: 37970340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
    Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
    J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma.
    Du M; Peng Y; Li Y; Sun W; Zhu H; Wu J; Zong D; Wu L; He X
    Cell Death Discov; 2022 Feb; 8(1):53. PubMed ID: 35136045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N
    Zheng X; Li S; Yu J; Dai C; Yan S; Chen G; Sun C
    Transl Cancer Res; 2023 Apr; 12(4):992-1005. PubMed ID: 37180667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.
    Zhu K; Gao T; Wang Z; Zhang L; Tan K; Lv Z
    Cell Death Discov; 2023 May; 9(1):151. PubMed ID: 37156775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF2BP3 is an essential N
    Xu X; Cui J; Wang H; Ma L; Zhang X; Guo W; Xue X; Wang Y; Qiu S; Tian X; Miao Y; Wu M; Yu Y; Xu Y; Wang J; Qiao Y
    Mater Today Bio; 2022 Dec; 17():100503. PubMed ID: 36457846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF2BP3‑stabilized SIX4 promotes the proliferation, migration, invasion and tube formation of ovarian cancer cells.
    Han J; Hu X
    Mol Med Rep; 2022 Jul; 26(1):. PubMed ID: 35616130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of m6A Reader IGF2BP3 Inhibited Hypoxia-Induced Cell Migration and Angiogenesis by Regulating Hypoxia Inducible Factor-1α in Stomach Cancer.
    Jiang L; Li Y; He Y; Wei D; Yan L; Wen H
    Front Oncol; 2021; 11():711207. PubMed ID: 34621671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting the m
    Dai TT; Li YZ; Hu HT; Zhao YM; Peng HY; Bai WD; Wang JW
    World J Oncol; 2024 Feb; 15(1):100-113. PubMed ID: 38274714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The m6A reader IGF2BP3 preserves NOTCH3 mRNA stability to sustain Notch3 signaling and promote tumor metastasis in nasopharyngeal carcinoma.
    Chen B; Huang R; Xia T; Wang C; Xiao X; Lu S; Chen X; Ouyang Y; Deng X; Miao J; Zhao C; Wang L
    Oncogene; 2023 Nov; 42(48):3564-3574. PubMed ID: 37853162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner.
    Zhang X; Shi L; Sun HD; Wang ZW; Xu F; Wei JF; Ding Q
    Clin Transl Med; 2023 Sep; 13(9):e1427. PubMed ID: 37743642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m
    Chen LJ; Liu HY; Xiao ZY; Qiu T; Zhang D; Zhang LJ; Han FY; Chen GJ; Xu XM; Zhu JH; Ding YQ; Wang SY; Ye YP; Jiao HL
    Cell Death Dis; 2023 Sep; 14(9):581. PubMed ID: 37658049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF2BP3 promotes progression of gallbladder carcinoma by stabilizing KLK5 mRNA in N
    Zhang J; Yang K; Bu J; Yan J; Hu X; Liu K; Gao S; Tang S; Gao L; Chen W
    Front Oncol; 2022; 12():1035871. PubMed ID: 36313631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF2BP3 drives gallbladder cancer progression by m6A-modified CLDN4 and inducing macrophage immunosuppressive polarization.
    Qin J; Cui Z; Zhou J; Zhang B; Lu R; Ding Y; Hu H; Cai J
    Transl Oncol; 2023 Nov; 37():101764. PubMed ID: 37643553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
    Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
    J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting IGF2BP3 in Cancer.
    Liu X; Chen J; Chen W; Xu Y; Shen Y; Xu X
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability.
    Zhang N; Shen Y; Li H; Chen Y; Zhang P; Lou S; Deng J
    Exp Mol Med; 2022 Feb; 54(2):194-205. PubMed ID: 35217832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STRIP2 motivates non-small cell lung cancer progression by modulating the TMBIM6 stability through IGF2BP3 dependent.
    Zhang X; Chen Q; He Y; Shi Q; Yin C; Xie Y; Yu H; Bao Y; Wang X; Tang C; Dong Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):19. PubMed ID: 36639675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis.
    Wu T; Zhang X; Xing L; Pan D; Liu P; Ding R; Yang R; Yang X; Li Y
    Dis Markers; 2022; 2022():5883101. PubMed ID: 35677634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression pattern analysis of m6A regulators reveals IGF2BP3 as a key modulator in osteoarthritis synovial macrophages.
    Lu Y; Zhang H; Pan H; Zhang Z; Zeng H; Xie H; Yin J; Tang W; Lin R; Zeng C; Cai D
    J Transl Med; 2023 May; 21(1):339. PubMed ID: 37217897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.